SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GE Vernova, Inc. engages in the electric power industry. It operates through the following segments: Power, Wind, and Electrification. The Power segment offers design, manufacture, and servicing gas, nuclear, hydro, and steam technologies, providing a critical foundation of dispatchable, flexible, stable, and reliable power. The Wind segment manages wind generation technologies, including onshore and offshore wind turbines and blades. The Electrification segment refers to the grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, storage, and orchestration of electricity from point of generation to point of consumption. The company was founded November 9, 2021 and is headquartered in Cambridge, MA.

GE Vernova Inc.

GE Vernova is trending as the market weighs a strong record backlog and raised long-term guidance against short-term volatility following an earnings miss and commentary regarding data center grid constraints. Investors remain divided, with many viewing the pullback as a buying opportunity given the company's central role in the multi-decade power infrastructure supercycle.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently the focus of intense community debate following the successful execution of its 13th Starship test flight, which included the deployment of next-generation Starlink satellites. While supporters highlight these technical milestones as evidence of long-term value, skeptics remain focused on the company's valuation, upcoming share lock-up expirations, and the ongoing volatility surrounding its IPO performance.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduro Clean Technologies is seeing increased investor attention as the company advances its Hydrochemolytic Technology, highlighted by positive pilot plant results and a recent uplisting to the Toronto Stock Exchange. The community is actively discussing the stock's potential for commercial scaling and its strategic expansion into paraffinic crude upgrading, while some participants remain focused on the firm's path to achieving long-term profitability.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is trending as investors debate the impact of its $1.5 billion acquisition of Personalis, which seeks to bolster its position in the competitive oncology and minimal residual disease (MRD) markets. While the community is dividedwith some bulls pointing to long-term data advantages and institutional backing as a strong entry opportunity, while bears cite dilution concerns and intense short interestmany are closely watching how the stock manages near-term price volatility following this major strategic deal.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is surging as investors react to a planned BLA resubmission for RP1 in advanced melanoma, fueled by reports of newfound regulatory flexibility following a recent FDA leadership shakeup. The community is actively debating the durability of the company's clinical data and the sustainability of the current rally given the stock's previous regulatory setbacks and ongoing funding requirements.

Aurora Innovation, Inc. engages in the design and development of automobile hardware, software, and provision of data services. It offers the Aurora Driver which allows a vehicle to drive itself. The company was founded by Christopher Urmson, Sterling Anderson and James Andrew Bagnell in 2017 and is headquartered in Pittsburgh, PA.

Aurora Innovation Inc - Ordinary Shares - Class A

Aurora Innovation is gaining significant community attention as investors track the upcoming rollout of its second-generation driverless trucks and anticipate key purchase order announcements. Discussion is heavily focused on the company's long-term scaling potential, internal hardware progress, and its ability to maintain execution timelines despite broader market headwinds.

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Albemarle is experiencing significant momentum as investors digest recent supply-side news, including export restrictions in key markets, which has heightened concerns over global lithium scarcity. The community is actively debating the stock's valuation and technical breakouts, with many traders focused on the broader macro tailwinds surrounding energy storage and long-term supply chain diversification.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is facing intense scrutiny from the investor community due to missed timelines regarding a key tenant announcement and significant underperformance relative to other data center stocks. Investors are actively debating the company's capital-intensive buildout, recent debt financing, and management's communication strategy while expressing frustration over the stock's failure to maintain momentum during broader sector rallies.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis is currently trending as shareholders and analysts dissect the company's prospects following recent regulatory developments and institutional portfolio adjustments. The community is actively debating the potential impact of pending immunotherapy reimbursement on valuation, while weighing concerns over cash runway and competitive pressures in the MRD diagnostics space.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

The ARK Innovation ETF is facing intense community scrutiny as investors debate its long-term performance and the high-conviction, often contrarian, trading strategy led by Cathie Wood. Discussions frequently highlight the fund's significant underperformance compared to broader market indices like the QQQ and S&P 500, fueling polarized debates over the viability of her growth-focused investment thesis.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Raymond James y&#39;day🏁 $MPLT and said: We are initiating coverage of MapLight Therapeutics (MPLT) at Strong Buy with a $46 target price. 
$BMY  OTSKY ABBV NBIX LBRX RVPH ATAI TEVA ITCI 
Here&#39;s what Raymond James had to say: https://x.com/Quantumup1/status/2070133195882836133?s=20

Raymond James y'day🏁 $MPLT and said: We are initiating coverage of MapLight Therapeutics (MPLT) at Strong Buy with a $46 target price.$BMY OTSKY $ABBV NBIX LBRX RVPH ATAI TEVA ITCIRaymond James added-We believe the risk/reward into ML-007C-MAs Ph2 ZEPHYR readout by mid-August... https://t.co/Ix3rHbutg8

X (Formerly Twitter)

quantumup on X (formerly Twitter): "Raymond James y'day🏁 $MPLT and said: We are initiating coverage of MapLight Therapeutics (MPLT) at Strong Buy with a $46 target price.$BMY OTSKY $ABBV NBIX LBRX RVPH ATAI TEVA ITCIRaymond James added-We believe the r...

Craig-Hallum⬇️ $MPLT-$40⬅️$43—reit-Buy—said—ML-004 Ph2 IRIS results were mixed but not thesis‍-breaking—missed 1° in social comm—but a meaningful benefit in a defined adolescent subgroup for irritability w/ &gt;tolerability than existing APs 
$JNJ $BMY - OTSKY DFTX 
H.C. Wainwright reiterated MapLight Therapeutics Buy; $45 and here is what the analyst had to say: https://x.com/Quantumup1/status/2069496992699437443?s=20

Craig-Hallum⬇️ $MPLT-$40⬅️$43-reit-Buy-said-ML-004 Ph2 IRIS results were mixed but not thesis‍-breaking-missed 1° in social comm-but a meaningful benefit in a defined adolescent subgroup for irritability w/ >tolerability than existing APs$JNJ $BMY - OTSKY DFTXH.C. Wainwright... https://t.co/O2kgEbBPsU

quantumup on X (formerly Twitter): "Craig-Hallum⬇️ $MPLT-$40⬅️$43-reit-Buy-said-ML-004 Ph2 IRIS results were mixed but not thesis‍-breaking-missed 1° in social comm-but a meaningful benefit in a defined adolescent subgroup for irritability w/ >tolerabi...

StockTwits Web

MapLight Therapeutics Inc.

Johnson & Johnson

Bristol-Myers Squibb Co.

Quantumup

Needham⬆️ $MPLT&#39;s PT to $45, from $42,⬆️ML-007-MC aka ML-007PAC PoS to 60 % and reiterated Buy. 
$ABBV $BMY JNJ OTSKY NBIX LBRX TEVA ATAI RVPH 
Needham said -- We recently met with management following which we remain optimistic for the upcoming Ph 2b ZEPHYR data readout for ML-007-MC in schizophrenia by mid-August, based on mtg commentary that it continues to see discontinuation and dose step down rates on a blinded basis trend below its expectations. 
 
We are increasing the POS from 55% to 60% which takes our PT to $45. 
 
In this note, we also highlight what we believe a positive ZEPHYR data could look like and potential readthroughs from ADEPT readout later this year. 
 
We expect the momentum in MPLT to continue with the readout of ZEPHYR and ADEPT studies this year.

 and said: We are initiating coverage of MapLight Therapeutics (MPLT) at Strong Buy with a $46 target price. 


  OTSKY ABBV NBIX LBRX RVPH ATAI TEVA ITCI 
Here's what Raymond James had to say: 